LIPOCINE INC. Revenue from Contract with Customer, Excluding Assessed Tax
LIPOCINE INC. (LPCN) reported Revenue from Contract with Customer, Excluding Assessed Tax of $54.99 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-10.
Discontinued › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2023-08-10
- LIPOCINE INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- LIPOCINE INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2023-03-31 was $54.99K.
- LIPOCINE INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- LIPOCINE INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- LIPOCINE INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $500.00K, a 96.90% decline from fiscal 2021.
- LIPOCINE INC. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $16.14M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $54.99K 10-Q · filed 2023-08-10 | $54.99K derived: sum of 3 quarters · filed 2023-08-10 | $54.99K derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | $54.99K 10-Q · filed 2023-05-11 | $54.99K derived: sum of 2 quarters · filed 2023-05-11 | $54.99K derived: sum of 3 quarters · filed 2023-05-11 | $554.99K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $0.00 derived: sum of 2 quarters · filed 2023-03-10 | $500.00K derived: sum of 3 quarters · filed 2023-08-10 | $500.00K 10-K · filed 2023-03-10 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $500.00K derived: sum of 2 quarters · filed 2023-08-10 | $500.00K 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $500.00K 10-Q · filed 2023-08-10 | $500.00K 10-Q · filed 2023-08-10 | ||
| 2021-12-31 | $16.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $16.14M derived: sum of 2 quarters · filed 2023-03-10 | $16.14M 10-K · filed 2023-03-10 | |
| 2021-09-30 | $54.99K 10-Q · filed 2022-11-09 | $54.99K 10-Q · filed 2022-11-09 | ||
| 2020-12-31 | $0.00 10-K · filed 2022-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |